Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
ATOS
ATOS News & Events
-
Add to Watchlist
Trade ATOS
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
ATOS News
Atossa Therapeutics Provides Strategic Update on Clinical Progress and Future Directions
Feb 11 2026
PRnewswire
Atossa Therapeutics Provides Update on Clinical Progress and FDA Feedback
Feb 11 2026
Newsfilter
Atossa Receives Rare Pediatric Disease Designation for (Z)-endoxifen
Feb 05 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Named One of Top 50 Healthcare Technology CEOs of 2025
Jan 21 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Recognized as Top 50 Healthcare Technology CEO of 2025
Jan 21 2026
Newsfilter
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
Jan 20 2026
NASDAQ.COM
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Stock Rises 12.98%
Jan 17 2026
NASDAQ.COM
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Jan 16 2026
Newsfilter
Show More News
ATOS Events
01/30 20:00
Atossa Genetics Trading Halted, News Pending
Atossa Genetics trading halted, news pending
01/16 16:50
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-endoxifen
Atossa Therapeutics announced that the U.S. FDA Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy.
01/15 21:40
Atossa Therapeutics' (Z)-endoxifen Granted FDA Orphan Designation
Atossa Therapeutics' (Z)-endoxifen was granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, according to a post to the agency's website.
Show More Events
ATOS Monitor News
No data
ATOS Earnings Analysis
No Data
People Also Watch
